Anticoagulants are defined as the class of drugs that helps to prevent blood coagulation or increases the clotting time. They are also referred as blood thinners, but these medications actually don’t result in thinning of blood, instead helps in preventing the formation of blood clots or breaks already formed blood clots that develop in patient’s blood vessels or in heart. In absence of treatment, these clots block the circulation of blood leading to stroke or heart attack.
As a part of its mechanism, anticoagulants interfere with the proteins known as factors, which are responsible for coagulation process and disturbs its operations deteriorating their coagulating capability, leading to prevention of clot formation. Anticoagulants sometimes results in excessive bleeding which results in harmful effects.
Anticoagulants being the major part of the first line treatment of heart diseases including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and stroke have been used extensively across the globe. Moreover, growing prevalence of coagulation disorders coupled with the aging population has increased the demand for anticoagulant drugs consequently leading to increased revenue generation. Launch of four patented drugs in the market in newly formed anticoagulants drug class, novel oral anticoagulants (NOACs) in between 2008 and 2014 has also resulted in high revenue generation for the total anticoagulants market as patented drugs are expensive in nature. Global anticoagulants market has been valued at USD ~ million in 2013 which increased to USD ~ million in 2015, exhibiting a CAGR of ~% in between 2013 and 2015.
For more information about the publication, refer to below link:
Ankur Gupta, Head Marketing & Communications